Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models-Reference-Cited by-同舟云学术

Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models

Published:2020-10-21 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Yeh Chun-Chieh,Liao Pei-Ying,Pandey Sudhir,Yung Su-Yung,Lai Hsueh-Chou,Jeng Long-Bin,Chang Wei-Chun,Ma Wen-Lung

Funder

Ministry of Science and Technology, Taiwan

National Health Research Institutes

China Medical University Hospital

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference36 articles.

1. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;El-Serag;Gastroenterology,2007

2. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations;Lodato;World J Gastroenterol,2006

3. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience;Fan;Ann Surg,2011

4. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma;Guo;World J Gastroenterol,2014

5. Metronomic chemotherapy;Maiti;J Pharmacol Pharmacother,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parecoxib inhibits tumorigenesis and angiogenesis in hepatocellular carcinoma through ERK–VEGF/MMPs signaling pathway;IUBMB Life;2024-06-14

2. Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-01

3. A Novel 3D Culture Scaffold to Shorten Development Time for Multicellular Tumor Spheroids;International Journal of Molecular Sciences;2022-11-12

4. Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model;Scientific Reports;2021-10-13